Niloofar Rahmani

Array ( [id] => 12239894 [patent_doc_number] => 20180072758 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-15 [patent_title] => '5HT3 RECEPTOR ANTAGONISTS' [patent_app_type] => utility [patent_app_number] => 15/610382 [patent_app_country] => US [patent_app_date] => 2017-05-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31049 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15610382 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17649639 [patent_doc_number] => 11352353 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-06-07 [patent_title] => Heterocyclic compound serving as FGFR4 inhibitor [patent_app_type] => utility [patent_app_number] => 16/304826 [patent_app_country] => US [patent_app_date] => 2017-05-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13522 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16304826 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12022163 [patent_doc_number] => 20170312263 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-02 [patent_title] => 'SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS' [patent_app_type] => utility [patent_app_number] => 15/603286 [patent_app_country] => US [patent_app_date] => 2017-05-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51787 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15603286 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16429445 [patent_doc_number] => 10829512 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-11-10 [patent_title] => Selective disulfidation reagent using nitrogen-containing compound and method for producing disulfide-containing compound [patent_app_type] => utility [patent_app_number] => 16/303008 [patent_app_country] => US [patent_app_date] => 2017-05-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 10 [patent_no_of_words] => 14138 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 626 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16303008 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11943218 [patent_doc_number] => 20170247369 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-31 [patent_title] => 'BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR ANTAGONISTS' [patent_app_type] => utility [patent_app_number] => 15/595107 [patent_app_country] => US [patent_app_date] => 2017-05-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 26622 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15595107 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12058558 [patent_doc_number] => 20170334903 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-23 [patent_title] => 'METHOD OF PREPARING GLUCOSYLCERAMIDE SYNTHASE INHIBITORS' [patent_app_type] => utility [patent_app_number] => 15/593440 [patent_app_country] => US [patent_app_date] => 2017-05-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4894 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15593440 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13761023 [patent_doc_number] => 10172840 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-01-08 [patent_title] => Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof [patent_app_type] => utility [patent_app_number] => 15/584459 [patent_app_country] => US [patent_app_date] => 2017-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 21940 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 1481 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15584459 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15977921 [patent_doc_number] => 10669268 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-06-02 [patent_title] => Bicyclic derivatives [patent_app_type] => utility [patent_app_number] => 15/583679 [patent_app_country] => US [patent_app_date] => 2017-05-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33147 [patent_no_of_claims] => 55 [patent_no_of_ind_claims] => 13 [patent_words_short_claim] => 10 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15583679 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11866109 [patent_doc_number] => 20170233393 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-17 [patent_title] => 'BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME' [patent_app_type] => utility [patent_app_number] => 15/583238 [patent_app_country] => US [patent_app_date] => 2017-05-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 92216 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15583238 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13222735 [patent_doc_number] => 10125132 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-11-13 [patent_title] => Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders [patent_app_type] => utility [patent_app_number] => 15/583161 [patent_app_country] => US [patent_app_date] => 2017-05-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 77920 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 309 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15583161 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12247291 [patent_doc_number] => 09920054 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-03-20 [patent_title] => 'Methyl- and trifluoromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof' [patent_app_type] => utility [patent_app_number] => 15/581310 [patent_app_country] => US [patent_app_date] => 2017-04-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 68011 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 5 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15581310 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13127411 [patent_doc_number] => 10081626 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-09-25 [patent_title] => 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists [patent_app_type] => utility [patent_app_number] => 15/496269 [patent_app_country] => US [patent_app_date] => 2017-04-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 3 [patent_no_of_words] => 40968 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 7 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15496269 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14277023 [patent_doc_number] => 20190135796 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-09 [patent_title] => EZH2 INHIBITORS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/095188 [patent_app_country] => US [patent_app_date] => 2017-04-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 59198 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16095188 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14277023 [patent_doc_number] => 20190135796 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-09 [patent_title] => EZH2 INHIBITORS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/095188 [patent_app_country] => US [patent_app_date] => 2017-04-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 59198 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16095188 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11851630 [patent_doc_number] => 20170226122 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-10 [patent_title] => 'ARTEMISININ DERIVATIVES, METHODS FOR THEIR PREPARATION AND THEIR USE AS ANTIMALARIAL AGENTS' [patent_app_type] => utility [patent_app_number] => 15/492180 [patent_app_country] => US [patent_app_date] => 2017-04-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 26235 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15492180 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14697551 [patent_doc_number] => 10376497 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-08-13 [patent_title] => Anti-fibrotic pyridinones [patent_app_type] => utility [patent_app_number] => 15/492828 [patent_app_country] => US [patent_app_date] => 2017-04-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 82313 [patent_no_of_claims] => 37 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 369 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15492828 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11993905 [patent_doc_number] => 20170298060 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-19 [patent_title] => 'PYRROLOPYRIDINE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/490003 [patent_app_country] => US [patent_app_date] => 2017-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31529 [patent_no_of_claims] => 56 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15490003 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11880737 [patent_doc_number] => 09751896 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2017-09-05 [patent_title] => 'Asymmetric 7-N isatin dimer Schiff base compounds with antitumor activities and a method of preparing the same' [patent_app_type] => utility [patent_app_number] => 15/489706 [patent_app_country] => US [patent_app_date] => 2017-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6674 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 10 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15489706 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11977462 [patent_doc_number] => 20170281616 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-05 [patent_title] => 'MORPHINAN COMPOUNDS' [patent_app_type] => utility [patent_app_number] => 15/488064 [patent_app_country] => US [patent_app_date] => 2017-04-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 16499 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15488064 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12023561 [patent_doc_number] => 20170313659 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-02 [patent_title] => 'COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS' [patent_app_type] => utility [patent_app_number] => 15/483413 [patent_app_country] => US [patent_app_date] => 2017-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25277 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15483413 [rel_patent_id] =>[rel_patent_doc_number] =>)